Tenth of the "ASCO Direct™ China" webinar series: Immunotherapy for Hepatocellular Carcinoma

About this Event

Webinar Date:

  • China Time: Saturday September 19th, 9 :00AM
  • US EST Time: Friday, September 18th, 9:00PM
  • US PST Time: Friday, September 18th, 6:00PM
  • Tokyo Time: Saturday, Sept. 19, 10:00 AM

Conference Language: English

Venue: Live Zoom Webinar

Webinar Agenda

► Chairs:

  • Prof. George Fisher, Medical Oncology, Stanford University
  • Prof. Masatoshi Kudo, Professor, Kindai University Faculty of Medicine
  • Prof. Minshan Chen, Sun Yat-sen University Cancer Center

Presentations:

Keynote-524 Study

  • Prof. Andrew X. Zhu, Harvard Medical School

Final results of a randomized, open label, perioperative Phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

  • Prof. Ahmed O Kaseb, MD Anderson Cancer Center

Data interpretation and clinical practice sharing of Tislelizumab in treatment of liver cancer

  • Prof. Zhongguo Zhou, Sun Yat-Sen University Cancer Center

Pharmaceutical advantages of Tislelizumab

  • Prof. Hongyun Wang, Peking Union Medical College Hospital

Panel Discussion

Chairs

  • Prof. George Fisher, Medical Oncology, Stanford University
  • Prof. Masatoshi Kudo, Kindai University Faculty of Medicine
  • Prof. Minshan Chen, Sun Yat-sen University Cancer Center

Guests

  • Prof. Andrew X. Zhu, Harvard Medical School 
  • Prof. Ahmed O Kaseb, MD Anderson Cancer Center
  • Prof. Hongyun Wang, Peking Union Medical College Hospital
  • Prof. Tianqiang Song, Tianjin Medical University Cancer Institute & Hospital
  • Prof. Feng Xia, The First Hospital Affiliated to AMU (Southwest Hospital)
  • Prof. Xu Che,  Cancer Hospital Chinese Academy of Medical Sciences (Shenzhen Center)
  • Prof. Bin Yi, Shanghai Eastern Hepatobiliary Surgery Hospital

Speakers and Panelists Bio

          

Prof. George Fisher, Medical Oncology, Stanford University

Dr. George Fisher is a Professor of Medical Oncology at Stanford University where he specializes in gastrointestinal cancers. He received his PhD in Cancer Biology and did all of his medical training at Stanford. Dr. Fisher is co-chair of the GI Committee for ECOG-ACRIN and serves on the NCI GI Steering Committee which is responsible for approving all randomized GI cancer trials within the National Cancer Trials Network (NCTN). His primary interest is in the design and conduct of therapeutic trials but he also collaborates with colleague in molecular biomarker and imaging research.

          

Prof. Masatoshi Kudo, Kindai University Faculty of Medicine

Masatoshi Kudo studied Medicine at Kyoto University and graduated in 1978. Following this, he completed a clinical fellowship in Kobe City General Hospital followed by a research fellowship at the University of California Davis Medical Center in USA and Kyoto University Graduate School of Medicine, where he received his PhD degree in Medical Science in 1987 Professor Kudo is currently a Professor and Chairman at the Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine since 1999 and the Executive Board Member of Kindai University.

Professor Kudo has published 632 International scientific peer review papers in well-regarded journals in addition to 842 domestic scientific papers. He has given 340 invited lectures in the area of his expertise on numerous occasions to international audiences. He serves as an Executive Council Board Member for Liver Cancer Study Group of Japan (LCSGJ), Chairman of Nationwide Survey Committee of LCSGJ, and a representative of LCSGJ Head Office. Professor Kudo is also a President of the Japan Society of Ultrasonics in Medicine (JSUM), President of Asia-Pacific Primary Liver Cancer Association (APPLE), Immediate Past President of WFUMB, President of AFSUMB, an Executive Board Member of Japan Society of Hepatology (JSH), a Founding Board member of International Liver Cancer Association (ILCA). He is also serving as an Editor-in-Chief of LlVER CANCER (Karger).

His research interest is "Diagnosis and treatment of HCC". Professor Kudo is the first author of “Consensus-based Practice Manual of HCC Proposed by Japan Society of Hepatology" published in 2007, 2010 and 2014 revised version.

           

Prof. Minshan Chen, Sun Yat-sen University Cancer Center

Professor Chen is the Chief of Liver Surgery Department in Sun Yat-sen University Cancer Center. He also is the Elected Chairman of CSLC (Chinese Society of Liver Cancer ) and the Chairman of Liver Cancer Association in Guangdong Province. Professor Chen is a surgeon and also perform hundreds RFA and TACE for HCC every year. He has thousands experience in the HCC treatment with surgical resection, RFA and TACE respectively. The research interesting of Professor Chen is Multidisciplinary management of HCC, including surgery, local ablation, embolization, systemic therapy and so on, especially radiofrequency ablation (RFA).

The Main Published Papers in recent years:

• Prognostic Nomogram for Patients with Unresectable Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization. Journal of hepatology. 2015 Jul;63(1):122-30.

• Radiofrequency Ablation with or without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial Journal of Clinical Oncology. Feb 1,2013:426-432.

• Radiofrequency Ablation versus Open Hepatic Resection for Elderly Patients (65 years) with very early or early Hepatocellular Carcinoma. Cancer. 2013 Nov 1;119(21):3812-20.

• Roles Played by Chemolipiodolization and Embolization in Chemoembolization for Hepatocellular Carcinoma: Single-Blind, Randomized Trial. J Natl Cancer Inst. 2013 Jan 2;105(1):59-68.

• A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 2006; 243(3):321-328.

           

Prof. Andrew X. Zhu, Harvard Medical School 

Prof. Andrew X. Zhu is Director of Jiahui International Cancer Center, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma.

As a widely published author, Dr. Zhu has served as a principle investigator in many clinical trials in HCC, cholangiocarcinoma and other gastrointestinal cancers. An internationally recognized leader in HCC and cholangiocarcinoma, he led the pivotal studies of developing several molecularly targeted, immunotherapeutic agents, and combination regimens in liver cancers which led to regulatory approval and studying the predictive and surrogate molecular and imaging biomarkers. He and his colleagues initially identified the presence of IDH mutations and the resistance mechanism to FGFR inhibitor in cholangiocarcinoma. He is a founding member of the International Liver Cancer Association, Fellow of American College of Physicians, and a member of ASCO and AACR. Dr. Zhu has served on the Hepatobiliary Cancer committee of the National Comprehensive Cancer Network, the Grants Selection Committee of ASCO, the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee, the American Joint Committee on Cancer Hepatobiliary Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases, and the Clinical Advisory Board of The Cholangiocarcinoma Foundation. He has received several awards for his work, including V Foundation Translational Research Award, Lorenzo Cappussotti Award, and Jonathan Kraft Translational Award.

          

Prof. Ahmed O Kaseb, MD Anderson Cancer Center

Dr. Kaseb is a Professor of GI Medical Oncology and leads HCC program at MD Anderson and is the Clinical PI and Director of MD Anderson SPORE NIH grant in HCC. Dr. Kaseb received his medical degree from Cairo University in 1996, and trained at University of Michigan, Wayne State University, and Henry Ford Hospital, in Michigan. He joined MD Anderson in 2007 and his research developed several protocols in the treatment and staging of HCC. His multidisciplinary teamwork has received several federal, foundation and pharmaceutical funding for dozens of projects and clinical trials, authored and co-authored over 100 papers and editorials. He currently serves on national ASCO and NCI HCC committees, and serves as the Editor-in-Chief of the international journal; “Journal of Hepatocellular Carcinoma”. He is the founder and steering committee chairman of the newly launched HCC international consortium that involves 8 international universities.

          

Prof. Zhongguo Zhou, Sun Yat-Sen University Cancer Center

Multidisciplinary management of hepatocellular carcinoma, including surgery, local ablation, embolization, target&systemic therapy, both in clinical and basic research.

Grants (Principle investigator):

• Mechanism of TACC3 mediating recurrence and metastasis of hepatocellular carcinoma after radiofrequency ablation, National Natural Science Foundation of China, 2016.

• Young Clinical Medical Scientist Project of Sun Yat-sen University Cancer Center, 2017.

• TACC3 regulation of stem cell like characteristics, invasion and metastasis of hepatocellular carcinoma, Guangdong Key Laboratory of Liver Disease Research, 2017.

• Antitumor effect of Pim kinase inhibitor on colon cancer , Guangdong Academy of medical science and Technology Research Fund, 2012.

Publications (Corresponding/First Author, Last 1 years):

• Chen J C, Wang J C, Pan Y X, Yi M J, Chen J B, Wang X H, Fu Y Z, Zhang Y J, Xu L, Chen M S, Zhang R X, Zhou Z G. Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial [J]. Am J Cancer Res, 2020, 10(5): 1467-1476.

• Pan Y X, Wang J C, Lu X Y, Chen J B, He W, Chen J C, Wang X H, Fu Y Z, Xu L, Zhang Y J, Chen M S, Lai R C, Zhou Z G. Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: A double-blind randomized clinical trial [J]. Surgery, 2020, 167(6): 933-941.

• Pan Y X, Long Q, Yi M J, Chen J B, Chen J C, Zhang Y J, Xu L, Chen M S, Zhou Z G. Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A real world single center study [J]. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, 46(4 Pt A): 548-559.

• Zhou Z G, Chen J B, Zhang R X, Ye L, Wang J C, Pan Y X, Wang X H, Li W X, Zhang Y J, Xu L, Chen M S. Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients [J]. Cancer Commun (Lond), 2020

          

Prof. Hongyun Wang, Peking Union Medical College Hospital

Vice Director of Beijing Key Laboratory of Clinical PK/PD, Director of Bioassay Lab of Clinical Pharmacology Research Center, Peking Union Medical College Hospital

1994-1998, B.S. major in pharmacy, China Pharmaceutical University; 1998-2003, Ph.D. major in pharmacology, Peking Union Medical College. During Mar. 2008 to Sep. 2009, Dr wang worked as a post-doc in Massachusettes General Hospital Affiliated to Harvard Medical School. Dr wang’s research is focused on clinical pharmacology, pharmacokinetics and drug metabolism. As a PI or sub-PI, Dr. wang participated in over 80 early clinical pharmacology studies including first-in-human studies, bridging pharmacokinetic studies, bioequivalence studies. So far he has published over 70 papers and authored 30 of them peer reviewed English journals.

• Committee Member of Chinese Clinical Pharmacological Society,

• Committee Member of Chinese Pharmacometrics Society,

• Committee Member of Chinese Mass Spectrometry Society, Vice

• Chairman of Committee of Beijing Drug Metabolism, Experts reviewers of CDE NMPA and CFDI.

            

Prof. Tianqiang Song, Tianjin Medical University Cancer Institute & Hospital

Professor Song is good at radical operation, standardized treatment and individualized comprehensive treatment of liver cancer, gallbladder cancer, high bile duct cancer and pancreatic cancer. As a core member of the key team of liver transplantation, he participated in and completed the first orthotopic liver transplantation, living donor liver transplantation and autologous liver transplantation in Tianjin Cancer Hospital. He took the lead in carrying out a series of new and difficult operations in the Hospital, such as "laparoscopic exploration and staging of abdominal tumors and resection of liver tumors", "new cholangiojejunostomy and pancreaticojejunostomy", "Fast Track hepatectomy", "Hanging Maneuver hepatectomy", "open and laparoscopic radiofrequency ablation of liver cancer". At the same time, the detection of liver reserve function and the analysis system of three-dimensional liver surgery plan were first applied in clinical practice, the concept of precise hepatectomy was strengthened and achieved good results.

• Standing committee of Oncology Branch of Chinese Medical Association

• Vice chairman of Nano-tumor Committee of China Anticancer Association

• Standing committee of Department of Oncology, Surgical Branch of Chinese Medical Association

• Standing committee of Hepatobiliary and Pancreatic Professional Committee of China Medical Education Association

• Secretary-General of Professional Committee on Hepatocellular carcinoma of Tianjin Anticancer Association

          

Prof. Feng Xia, The First Hospital Affiliated to AMU (Southwest Hospital)

Chief physician, Division of liver surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China

• Member of Committee of Liver Cancer of the Chinese Anti-Cancer Association

• Member of Committee of Cancer metastasis of the Chinese Anti-Cancer Association

• Visiting scholar, Department of Surgery, Oxford University

• Honorary clinical researcher, WK, Yee Fellowship, Department of Surgery, University of HongKong

• Member of executive Committee of Liver Cancer, Chinese Society of Clinical Oncology (CSCO)

• Member of Committee of the Liver Cancer, Chinese Medical Doctor Association

• Chairman of Committer of Hepatic Hemangioma, Chinese Branch, International Hepato-Pancreato-Biliary Association(IHPBA)

• Membe of Professional Committee on Treatment of Colorectal Cancer with Hepatic Metastasis, China International Exchange and Promotion Association for Medical and Healthcare

• Member of the professional committee on hepatobiliary diseases, China International Exchange and Promotion Association for Medical and Healthcare

           

Prof. Xu Che,  Cancer Hospital Chinese Academy of Medical Sciences (Shenzhen Center)

Chief Physician, Doctoral Supervisor and Director of Hepatopancreatobiliary Surgery Department, Cancer Hospital Chinese Academy of Medical Sciences (Shenzhen Center)

• Member of International Hepato-Pancreato-Biliary Association (IHPBA)

• Member of Asia-Pacific Hepato-Pancreato-Biliary Association (A-PHPBA)

• Youth Member of Oncology Professional Committee, Chinese Medical Assosication

• Member of Hepatopancreatobiliary Group, Enhanced Recovery after Surgery Expert Committee, National Health Commission of the People's Republic of China

• Secretary General of Pancreatic Diseases Branch of China International Exchange and Promotion Association for Medical and Healthcare

• Vice Chairman of Abdominal Oncology Professional Committee, China Medical Education Association

• Vice Leader of Youth Group, Pancreatic Diseases Branch of China International Exchange and Promotion Association for Medical and Healthcare

• Vice leader of Minimally Invasive Surgery Group, Pancreatic Diseases Branch of China International Exchange and Promotion Association for Medical and Healthcare

            

Prof. Bin Yi, Shanghai Eastern Hepatobiliary Surgery Hospital

MD & PhD, Associate Professor, Associate Senior Surgeon, Master Supervisor;Deputy Director of Department I of Biliary Tract, Eastern Hepatobiliary Surgery Hospital;Deputy Director of Biliary Tract Tumor Center, Second Military Medical University

• Member of the Standing Committee & Chairman of the Youth Committee, Society of Biliary Tract Neoplasm, China Anti-Cancer Association

• Secretary General of Biliary Tract Tumor Committee, Shanghai Anti-Cancer Association

• Member of the Surgery Group, Digestive Endoscopy Branch, Chinese Medical Association

• Member of Liver Tumor Comprehensive Treatment Committee, Shanghai Anti-Cancer Association

• Member of Pancreatology Group, Surgery Branch, Shanghai Medical Association

• Member of Biliary Calculus Committee, Chinese Branch, International Hepato-Pancreato-Biliary Association

• Visiting scholar, Hepatobiliary Center, Hôpital Paul Brousse, Université Paris-Sud

• Member of Association des Médecins et Biologistes Chinois en France


Immunotherapy for Hepatocellular Carcinoma

Abstract #: 4519

A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)

Abstract #: 486

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC

Abstract #: 4644

Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites


If you need to request a copy of the abstract, please send email to "webinars@eChinaHealth.com”.

Disclaimers: ASCO and eChinaHealth do not endorse any health care product, therapy, diagnostic test or device.

           

 

Organizers:

             

Partners:            

                              

Exclusive Live Streaming Platform:

                                          

Welcome

Welcome to john the ASCO China Conference WeChat Groups! You can follow up the latest on ASCO China conferences and network with fellow Chinese and global attendees. We will post the conference information including the links on recorded conference videos. Please use your WeChat to scan the QR code to join.